In contrast, an analysis of pooled data from three adjuvant trials of the Eastern Cooperative Oncology Group with anthracycline-based chemotherapies in 6885 patients revealed significantly poorer outcomes for obese patients (BMI ≥ 30) than for nonobese patients with hormone receptor-positive disease, but no negative impact of obesity on survival in patients with other breast cancer subtypes [6]. The gene discussed is NR4A1; the disease is breast cancer.